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Abstract 
Signaling through the Notch1 receptor has a pivotal role in early thymocyte 
development. Gain of Notch1 function results in the development of T-cell acute 
lymphoblastic leukemia (T-ALL) in a number of mouse experimental models, and activating 
Notch1 mutations deregulate Notch1 signaling in the majority of human T-ALLs. Notch2, 
another member of the Notch gene family, is preferentially expressed in mature B cells and is 
essential for marginal zone B-cell generation. Here, we report that 5 of 63 (~8%) diffuse large 
B-cell lymphomas (DLBCL), a subtype of mature B-cell lymphomas, have Notch2 mutations. 
These mutations lead to partial or complete deletion of the PEST domain, or a single amino 
acid substitution at the C-terminus of Notch2 protein. Furthermore, high-density 
oligonucleotide microarray analysis revealed that some DLBCL cases also have increased 
copies of the mutated Notch2 allele. In the Notch activation-sensitive luciferase reporter 
assay in vitro, mutant Notch2 receptors show increased activity compared with wild-type 
Notch2. These findings implicate Notch2 gain-of-function mutations in the pathogenesis of a 
subset of B-cell lymphomas, and suggest broader roles for Notch gene mutations in human 
cancers. 
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Introduction 
 Signaling through the Notch receptor, triggered by the binding of ligands expressed 
on neighboring cells, has a key role in determining cell fate in a variety of cell lineages, 
including lymphocytes 1, 2. In mammals, there are four Notch genes that encode structurally 
similar single-pass and heterodimeric transmembrane receptors. Ligand binding initiates a 
series of intramolecular cleavages, which eventually liberates the intracellular domain of the 
transmembrane subunit of the Notch receptor (ICN). The ICN is then translocated to the 
nucleus and creates a transcriptional activating complex with RBP-Jκ, a constitutive DNA 
binding protein. During these processes, Notch proteins are intricately regulated by 
glycosylation, endocytosis, recycling, phosphorylation, and ubiquitylation before and after 
ICN liberation. Many of these regulatory processes appear to modify the biologic activity of 
Notch 3. Notably, polyubiquitylation-based degradation is dependent on the PEST domain, 
located at the C terminus of the Notch protein. 
The physiologic roles of Notch1 and Notch2 have been clarified in mouse models, 
particularly in the lymphoid system. Notch1 is preferentially expressed in immature T cells 
and is essential for specification of early hematopoietic progenitors toward the T-cell fate and 
for early T-cell development in the thymus 4. In contrast, Notch2 is preferentially expressed in 
mature B cells and is required for the generation of a mature B-cell subset, known as splenic 
marginal zone B (MZB) cells in mice 5. Notch1 was originally identified as a transforming 
gene in human T-cell acute lymphoblastic leukemia (T-ALL) cells harboring the 
t(7;9)(q34;q34) chromosomal translocation 6. The N-terminal truncated form of Notch1 
expressed in this type of T-ALL cell can induce the development of T-ALL when expressed in 
bone marrow cells that are then transplanted into recipient mice 7. Importantly, more than 
50% of childhood and 30% to 40% of adult human T-ALL cases carry Notch1 mutations that 
  5 
lead to deregulated activation of Notch signaling 8-11, indicating that accelerated Notch 
signaling contributes to the development of human neoplasms. 
Two regions of the Notch1 gene are major targets of oncogenic mutations in T-ALL. 
Missense, insertion, and deletion mutations in the heterodimerization domains are thought to 
decrease the stability of the dimer, consisting of the extracellular and transmembrane subunits, 
which results in the progression of Notch1 cleavage without ligand stimulation 8, 12. The other 
series of mutations accumulate in the PEST domain and its N-terminally flanking 
transactivation domain. All these mutations cause partial or complete deletion of the PEST 
domain, which are considered to result in the prolonged half-life of Notch1 ICN, because the 
PEST domain is responsible for polyubiquitylation-based degradation of ICN 13. 
These lines of information about Notch genes led us to examine the possibility that 
deregulation of Notch2 signaling is involved in the development of mature B-cell lymphomas. 
We screened Notch2 gene mutations at the heterodimerization and PEST domains in 109 
B-cell lymphoma samples, and found mutations in 5 samples, all of which were diffuse large 
B-cell lymphomas (DLBCL). Interestingly, two of the five samples had an increased copy 
number of the mutated Notch2 allele, and in another sample of the five the total copy number 
of the Notch2 allele was increased. Furthermore, we confirmed that the mutation-carrying 
Notch2 receptors had increased activity when stimulated by a ligand in vitro. We postulate 
that gain-of-function mutations of Notch2 are involved in the pathogenesis of a subset of 
DLBCL. 
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Materials and methods 
Patient materials and genomic DNA preparation. Patients (n=109) with various B cell 
lymphomas were enrolled in the study after informed consent was obtained. The study design 
was approved by the ethics committees of the University of Tokyo and Aichi Cancer Center. 
Genomic DNA was extracted from cryopreserved samples using a commercial kit 
(PUREGENETM, Gentra, Minneapolis, MN). 
PCR-single-strand conformation polymorphism (SSCP). Based on the information of 
Notch1 mutations in T-ALL and the high similarity between Notch1 and Notch2 genes, we 
confined our mutation analysis to exons 26, 27, and 35 of Notch2 that correspond to the 
heterodimerization domains (exons 26 and 27) and the C-terminal region containing the 
transactivation and PEST domains (exon 34), respectively. Oligonucleotide primers designed 
to amplify whole exon 26 and exon 27, and five divided portions of exon 35 are listed in 
Supplemental Table 1. The 32P-labled PCR product was subjected to SSCP analysis as 
described in the literature 14. In brief, the PCR mixture was heated at 80ºC and applied to 5% 
polyacrylamide gel containing 10% glycerol. After 2 - 4 h electrophoresis with cooling, the 
gel was dried on filter paper and exposed to X-ray film. The PCR products were directly 
sequenced or bands with aberrant migration were excised from the gel and subjected to direct 
sequencing when indicated. 
High-density oligonucleotide microarray analysis. Genome-wide copy number detection 
analysis was performed as described previously 15. In brief, Affimetrix GeneChip Mapping 
100 k high-density oligonucleotide arrays (Affimetrix, Inc, Santa Clara, CA) were used and 
the data were analyzed using the CNAG algorithm. 
Fluorescence in situ hybridization. Bacterial artificial chromosome (BAC) clones 
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RP11-723d17 (Notch2) and RP11-80d6 (1q23.3) were used to evaluate the copy number of 
the Notch2 gene. BACs were obtained from the BAC/PAC Resource Center (Children’s 
Hospital, Oakland, CA). Fluorescence in situ hybridization experiments on interphase nuclei 
were performed as described previously 16. 
Quantitative real-time PCR for genomic DNA. For the copy number evaluation of the 
Notch2 gene by quantitative real-time PCR, genomic DNA was extracted from samples L8 
and W121672; a stomach cancer cell line (MKN45) that had a copy number loss at the 
Notch2 (1p13) locus (data from microarray analysis not shown); and normal peripheral blood 
mononuclear cells. The Notch2 gene dosage was measured using the primers: forward, 
TTCCCCAAGTGAGAGACATTT, and reverse, CAGACACTTCACAGAACAGAA, and 
normalized by the relative DNA quantities measured by real-time PCR using the control 
locus (2q35) primers: forward, TGGCTGATGAACTTTTGCAC, and reverse, 
AGCGGTTGAGGTCTGTGAAC. Student’s t-test was used for the statistical analysis. 
Immunohistochemistry. Tissue sections were mounted on silanated slides, deparaffinized 
with xylene, rehydrated with a series of graded ethanols, processed with an autoclave in 10 
mmol/l citrate buffer for 5 min, pH 6.0, treated with horse serum albumin to block 
nonspecific staining, and immunostained. The detection of antibody binding was visualized 
by the avidin biotin complex method using diaminobenzidine as the chromogen. The sections 
were counterstained with hematoxylin. 
Plasmid preparation. In the human full-length Notch2 cDNA (wtN2) (a gift from S. 
Artavanis-Tsakonas, Harvard University), the stop codon corresponding to the nonsense 
mutation (7454 C/T), the single-base deletion mutation corresponding to 7120Del, and the 
point mutation corresponding to 7614 G/A were introduced. Mutant primers were used for 
PCR and the resulting products were sequenced and used to replace the corresponding 
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fragment of wtN2 cDNA to create the Notch2 with the nonsense mutation and the R2453Q 
mutation (nsmN2, delstN2, and rqN2, respectively). These cDNAs were inserted in 
pTracerCMV (Invitrogen, Carlsbad, CA)  
Establishment of CHO(r) cells stably expressing wild-type and mutant human Notch2. 
CHO(r) cells were transfected with pTracerCMV/wtN2, pTracerCMV/nsmN2, 
pTracerCMV/delstN2, and pTracerCMV/rqN2, and selected for zeocin (400 µg/ml) resistance. 
The resulting zeocin-resistant cells were single-cell sorted using the anti-human Notch2 
monoclonal antibody (mAb). The anti-human Notch2 (MHN2-25, mouse IgG2a) mAb was 
generated by immunizing BALB/c mice with human Notch2-Fc (the Fc portion of human 
IgG1 was fused to the 22nd epidermal growth factor repeat of the extracellular region of 
human Notch2) and screening hybridomas producing mAbs specific for Notch2-Fc by ELISA. 
MHN2-25 reacted with CHO(r) cells expressing human Notch2, as demonstrated by flow 
cytometry (Supplemental Fig. 1).  
Western blot analysis. Immunoblotting was performed as described previously 17. In brief, 1 
x 106 wtN2/CHO(r), nsmN2/CHO(r), delstN2/CHO(r), and rqN2/CHO(r) cells were 
solubilized in 0.1 ml lysis buffer containing 1% NP-40, electrophoresed in 7.5% sodium 
dodecyl sulfate polyacrylamide gel, transferred onto Immobilon-P membrane (Millipore, 
Billerica, MA). It was then probed with a monoclonal antibody recognizing the intracellular 
domain of human and murine Notch2 (C651.6DbHN, University of Iowa Developmental 
Studies Hybridoma Bank, Iowa City, IA) and an alkaline phosphatase-conjugated secondary 
antibody (Promega, Madison, WI). 
Transcriptional activation assay. The luciferase assay was performed as described 
previously 17. In brief, 2 x 105 CHO(r) cells expressing wtN2, Notch2 with truncatation at 
2400 (nsmN2), Notch2 with truncation after 6 amino acids insertion at 2288 (delstN2), and 
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Notch2 with an R2453Q mutation (rqN2) were inoculoated in a 6-well dish and the next day 
transfected with the pGa981-6 luciferase reporter plasmid (2 µg) using the SuperfectTM 
transfection reagent (QIAGEN, Hilden, Germany). The β-galactosidase-expressing plasmid, 
pCMV/β-Gal (0.2 µg) was co-transfected when indicated. The cells were harvested after 3 h, 
suspended in 3 ml medium, and a 200 µl aliquot was re-plated in a 48-well dish coated with 
soluble human Delta1 (Delta1-Fc, a chimeric protein composed of the extracellular domain of 
human Delta1 and the Fc portion of human immunoglobulin G 18, 19, a gift from S. Sakano, 
Asahi Kasei). After 24 h incubation, the cellular extracts were used to measure luciferase and, 
when applied, β-galactosidase activities. Two independent clones were used to compare the 
luciferase activity of each Notch2 protein and bulk transfectants were used to evaluate the 
effect of DAPT (Calbiochem), a γ-secretase inhibitor. 
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Results 
Notch2 gene is mutated in a subset of DLBCL. Notch2 gene mutations were screened in 
109 B-cell lymphoma samples, including 63 DLBCLs, 18 follicular lymphomas, and 28 MZB 
cell lymphomas or mucosa-associated lymphoid tissue lymphomas. Exons 26 and 27, 
encoding the N- and C-terminal heterodimerization domains, and a portion of exon 34, 
encoding the PEST domain and its bilateral flanking regions, were amplified by polymerase 
chain reaction (PCR) using genomic DNA with the primers listed in Supplemental Table1 and 
examined for mutations using the single-strand conformational polymorphism (PCR-SSCP) 
method 20. 
Five distinct nucleotide changes were detected in 11 of the 109 B-cell lymphoma 
samples, exclusively in exon 34. Whereas two of the five changes detected in 6 of the 11 
samples were single nucleotide polymorphisms (SNP) without amino acid changes, the other 
3 nucleotide changes detected in the remaining 5 samples (Fig. 1 A-E) were thought to 
represent somatic mutations resulting in premature truncation or single amino acid 
substitution (Table 1). A nonsense mutation, C to T at nucleotide 7454 (based on the 
published human Notch2 sequence, NM_024408), in three cases (Fig. 1A-C) and a single 
base deletion at position 7120 in another case (Fig. 1D), led to premature truncation of the 
Notch2 protein (Table 1). These Notch2 proteins lacked a part or the entire region of the 
PEST domain. The other single nucleotide change, G to A at 7614, resulted in the 
replacement of arginine with glutamine on the C-terminal side of the PEST domain (Fig. 1E 
and Table 1). The G7614A change is not listed in the public SNP database 
(http://www.ncbi.nlm.nih.gov/projects/SNP/; as of October 23, 2007). In addition, the dose of 
the mutant A allele was unbalanced relative to the wild-type G allele (Fig. 1E), further 
decreasing the possibility of an SNP. Constitutive DNA was available in one case (W109539) 
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and was confirmed to be the wild-type sequence (Fig. 1F), which definitely concluded that 
the mutation in the tumor was somatic origin. 
Mutation-carrying cases show the same expression pattern of CD10, BCL6, and 
MUM-1. All five cases with Notch2 mutations were diagnosed as DLBCL, and were 
uniformly immunohistochemically negative for CD10 and positive for BCL6 and MUM-1 
(Fig. 2). We have reviewed 24 DLBCL subjects without Notch2 mutations for expression of 
CD10, BCL6 and MUM-1. The immunohistochemistry study revealed that CD10, BCL6, and 
MUM-1 were positive in 4, 19, and 16 subjects, respectively. Among these, the 
CD10-negative, BCL6-positive, and MUM-1-positive staining pattern was seen in 10 (data 
not shown). Thus, this pattern was seen in five out of five Notch2 mutation-carrying subjects 
and 10 out of 24 Notch2 mutation-negative subjects, making the comparison statistically 
significant (p=0.042; Fisher’s exact test). This estimation is consistent with the previous 
report 21 and indicates that CD10-negative, BCL6-positive, and MUM-1-positive DLBCL 
might represent a fraction of non-germinal center B-cell-like DLBCL (non-GCB-DLBCL), 
according to the immunohistchemistry-based DLBCL subclassification 21. DLBCL cases 
carrying the gain-of-function-type Notch2 mutations, thus, might constitute a discrete subset 
of non-GCB-DLBCL. 
Some mutation-carrying samples have an increased copy number of the mutated Notch2 
allele. Of particular interest is the fact that some oncogenic mutations are associated with 
increases in DNA copy number 22, 23. A high-density oligonucleotide microarray analysis 15 
was performed for 35 among 63 DLBCL samples in the current cohort to evaluate 
genome-wide copy number alterations. This analysis revealed an increased copy number of 
the Notch2 allele in the two samples, both of which carried the nonsense mutation. The other 
33 samples did not show Notch2 copy number alterations. In one sample (W109539), 
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amplification of the Notch2 locus in chromosome 1p was demonstrated by microarray (Fig. 
3A, left panel) and fluorescence in situ hybridization (Fig. 3B) analyses. An allele-specific 
copy number detection analysis revealed an increase in the copy number of a single Notch2 
allele (Fig. 3A, left panel). This allele must correspond to the allele carrying the mutated 
Notch2 gene because the mutated band was overwhelmingly dominant in the PCR-SSCP 
analysis (Fig. 1A). In the other sample (W121672) with a Notch2 copy number increase, the 
genomic region encompassing the Notch2 locus on chromosome 1p through the telomere of 
chromosome 1q had three copies, whereas most of the 1p region had only one copy (Fig. 3A, 
right panel). The Notch2 copy number increase was confirmed by a quantitative real-time 
PCR analysis (Fig. 3C). We were unable to determine whether the third Notch2 allele 
contained wild-type or mutant Notch2 in this sample. In the third sample carrying the 
nonsense mutation (L8), a change in the Notch2 copy number was not detected in the 
microarray analysis (data not shown) and quantitative PCR analysis revealed that the copy 
number was normal (Fig. 3C). Both Notch2 alleles in this sample, however, were likely to 
have the nonsense mutation, thus representing uniparental disomy, losing the wild-type 
Notch2, because the mutant band was overwhelmingly dominant in the PCR-SSCP analysis 
(Fig. 1C). Taken together, these findings indicate that some DLBCL samples have Notch2 
mutations and an increased copy number of the mutated Notch2 gene. 
Notch2 receptors with mutations have increased activity in vitro. To investigate the 
function of the Notch2 receptors encoded by mRNA with the nonsense mutation (nsmN2), 
the single-base deletion mutation (delst), and missense mutation (rqN2), we established 
CHO(r) cell lines 17 expressing wild-type Notch2, nsmN2, delstN2, and rqN2 [wtN2/CHO(r), 
nsmN2/CHO(r), delstN2/CHO(r), and rqN2/ CHO(r)] and obtained independent clones 
expressing each Notch2 protein at similar levels, using fluorescence-activated cell sorting 
with human Notch2-specific antibody (Fig. 4A; Supplemental Fig. 1). A Western blot analysis 
  13 
demonstrated that the expected sizes of the transmembrane subunit species were expressed at 
comparable levels (Fig. 4B). In a Notch-sensitive luciferase reporter assay 24, the luciferase 
activity was significantly increased in nsmN2/CHO(r), delstN2/CHO(r), and rqN2/CHO(r) 
cells, compared with that in wtN2/CHO(r) cells when stimulated with Delta1-Fc. Basal 
luciferase activities with control IgG also tended to be higher in the three mutant 
Notch2-expressing CHO(r) cells lines than that in wtN2/CHO(r) (Fig. 4C). These results 
indicated that all the three kinds of mutation-carrying Notch2 had significantly increased 
levels of transcriptional activity compared with wtN2, irrespective of the strength of the 
Delta1 stimulation. 
 To evaluate the effect of γ-secretase inhibitor on wtN2 and nsmN2, we added graded 
concentrations of DAPT to the Delta1-Fc-stimulated bulk wtN2/CHO(r) and nsmN2/CHO(r). 
The elevated luciferase activity was reproducible with the bulk nsmN2/CHO(r), which was 
reduced by DAPT in a concentration-dependent manner (Fig. 4D). The luciferase levels of 
both wtN2/CHO(r) and nsmN2/CHO(r) at 3 µM DAPT in the presence of Delta1-FC were below 
those in the presence of control IgG without DAPT, respectively, implying the spontaneous Notch2 
activity with only IgG in the culture system. The results also indicate that the increased Notch2 activity by 
the PEST domain deletion is still dependent on the γ-secretase activity.     
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Discussion 
The results of the present study demonstrated gain-of-function mutations of Notch2 
and increased copy numbers of the mutated Notch2 allele in a subset of DLBCL. Both 
nonsense mutations and single base deletion mutations that we found in Notch2 cause partial 
or complete deletion of the Notch2 PEST domain. Given the marked structural similarities 
between Notch1 and Notch2, these mutations are thought to prolong the half-life of Notch2 
ICN. In some T-ALL cell lines, both heterodimerization and PEST domain mutations lie in 
cis in the same Notch1 allele. The reporter transcriptional activity of Notch1 with these 
double mutations was remarkably higher than that of wild-type Notch1 and Notch1 with a 
single mutation at either the heterodimerization or PEST domain in the absence of exogenous 
ligand stimulation. The activity of Notch1 with a PEST domain deletion mutation alone was 
only marginally higher than that of wild-type Notch1 8. We did not detect mutations in either 
heterodimerization domain of Notch2 in the current cohort. It might be possible to identify 
those mutations if the number of samples is increased. With the PEST domain deletion alone, 
however, nsmN2 had a highly significant increase in activity compared with wtN2. Thus, 
there appears to be some disagreement between the effects of Notch1 PEST domain deletion 
and Notch2 PEST domain deletion, although difference in the experimental systems used in 
the two studies might cause such apparent disagreement. It remains to be determined whether 
similar mutations found in Notch1 and Notch2 have different biochemical and biologic 
significances. 
The activity was also increased in the rqN2, which has the 2453R/Q single amino 
acid substitution. This amino acid is located on the C-terminal side of the PEST domain, and 
it is unknown whether this change affects the structure or function of the PEST domain. 
Nevertheless, as the arginine residue is often a target of protein modification such as 
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methylation 25, 26, this amino acid change might convey a significant alteration in the protein 
function and be involved in lymphomagenesis. 
There are other examples of copy number increases associated with oncogenic gene 
alterations, such as double Philadelphia chromosomes (BCR/ABL copy number increase) in 
the blastic crisis of chronic myelogenous leukemia 27 and homozygous JAK2 mutations in 
polycythemia vera 22, 23, both of which represent clonal evolution and selection. In the present 
study, we showed that at least two (or possibly three) cases had increased copy numbers of 
the mutated Notch2 allele due to gene amplification or mitotic recombination. This finding 
agrees with the recent understanding that the allelic copy number increases after an 
oncogenic mutation are a common mechanism of further transformation and selection of 
neoplastic cells. 
Whether the presence of Notch2 gain-of-function mutations has a prognostic 
indicator or further define a clinical entity within DLBCL is yet to be clarified in future. 
Although the number of cases are still smalll, our finding that all five cases with Notch2 
mutations showed the same immunohistochemical staining pattern for CD10, BCL6, and 
MUM-1 might provide insight into this issue. DLBCL is highly heterogeneous clinically, 
morphologically, and genetically. The tissue microarray study based on immunostaining of 
the tissue samples identified three antigens (CD10, BCL6, and MUM-1) as useful markers to 
predict the results of mRNA expression array studies 28-30, and the staining pattern of these 
three antigens could be used to divide DLBCL cases into germinal center B-cell-like (GCB) 
and non-GCB groups 21. Whereas all the five cases carrying Notch2 mutations in our study 
belonged to the non-GCB group of DLBCL in this criterion, Troen, et al. have recently 
reported Notch2 mutations in two cases of MZB cell lymphomas 31. Positions of these 
mutations are different from those that we demonstrated, and their effect on the Notch2 
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function is not demonstrated. We did not find Notch2 mutations in MZB cell lymphomas in 
our cohort, yet the number of samples was not sufficient to draw conclusions. Although we 
were unable to find evidence that some or all the five cases carrying Notch2 mutations in our 
cohort are DLBCL transformed from MZB cell lymphoma, this might be an interesting 
possibility. 
Enhanced activation of Notch signaling by exogenous ligand stimulation or 
expression of constitutively active Notch proteins supports the growth of a variety of tumor 
cells, including chronic lymphocytic leukemia 32, non-Hodgkin lymphoma, and multiple 
myeloma 33 cells. Alternatively, inhibition of Notch signaling by γ-secretase inhibitors 
suppresses the growth of those tumor cells, in which enhanced Notch signaling might be 
involved in tumorigenesis 34. In contrast, a study of mice with a Notch1 deletion in 
keratinocytes revealed the tumor-suppressive feature of Notch signaling 35. In a similar 
context, Notch2 activation induces growth suppression in a wide range of B cell malignancies, 
raising the possibility that Notch2 functions as a tumor suppressor in B cells 36. Thus, there 
appears to be a controversy regarding whether Notch signaling has an oncogenic or 
anti-oncogenic role in mature B cell malignancies. It might be possible that Notch signaling 
can induce both growth suppression and tumor promotion in the B cell compartment, 
depending on the target window within the various developmental stages of B cells. 
Although  sledom lamina fo tnempoleved gnidulcni seiduts lanoitidda eriuqer lliw ti
hctoN eht rof elor eht tuoba noisulcnoc evitinifed a ward ot2 sisenegamohpmyl ni snoitatum , 
our observations in this study strongly indicate that deregulation of Notch2 signaling by 
somatic Notch2 gene abnormalities contributes to the development of a subset of DLBCL, the 
most frequent type of non-Hodgkin lymphoma. Developing inhibitors of individual Notch 
molecules, therefore, might provide a new strategy for the treatment of different kinds of 
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malignancies, including T-ALL and DLBCL.
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Figure legends 
Figure 1. Mutations of the Notch2 gene in DLBCL. PCR-SSCP and sequence analyses for 
samples having the nonsense mutation at 7454, C/T (W109539, W121672, L8). Arrowheads 
indicate shifted bands. The shifted bands in (A) and (C) are obviously dominant against the 
normal band, suggesting the small amount of normal tissue contamination and unbalanced 
ratio of mutant and normal alleles. Those in (B) and (E) are minor compared with the normal 
band, suggesting the contamination of normal tissues, and those in (C) are comparable with 
the normal band. The shifted bands were excised from the gel and the extracted DNA was 
sequenced for samples W121672 and W117336. (D) Sequence of DNA prepared from the 
bone marrow cells obtained from the patient W109539. 
Figure 2. Immunohistochemical staining of lymphoma specimens for CD10, BCL6, and 
MUM1. Antibodies used were anti-CD10 monoclonal antibody (56C6, Novocastra, Norwell, 
MA), anti-BCL6 monoclonal antibody (P1F6, Novocastra), and anti-human MUM1 
monoclonal antibody (MUM1p, Dako, Glostrup, Denmark). The detection of antibody 
binding was visualized by the avidin biotin complex method using diaminobenzidine as the 
chromogen. Microscope, Elipse 80i (Nikon). Original magnification, x200. Camera, 
Dxm1200F (Nikon). Acquisition software, Act-1 (Nikon). 
Figure 3. Copy number increases of mutated Notch2 allele in DLBCL. (A) High-density 
oligonucleotide microarray analysis using the CNAG program for samples W109539 and 
W121672. The copy number of the Notch2-encompassing allele is greatly increased in 
W109539 and mildly increased in W121672. Red arrow, centromere. (B) Fluorescence in situ 
hybridization analysis for sample W109539 using probes corresponding to Notch2 (green 
signals) and a reference sequence on 1q23.3 (red signals). (C) Copy number evaluation of the 
Notch2 gene by quantitative real-time PCR for samples L8 and W121672. The quantity of 
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genomic DNA, extracted from samples L8 and W121672; MKN45 [a stomach cancer cell 
line having a copy number loss at the Notch2 (1p13) locus]; and normal peripheral blood 
mononuclear cells (PBMNC), was normalized by real-time RT-PCR for the control locus 
(2q35). Statistical analysis (Student’s t-test) demonstrated that the Notch2 gene dose was 
unchanged in sample L8, and significantly increased in sample W121782, relative to the 
Notch2 gene dose in the PBMNC, whose mean level was adjusted to two copies. *, p<0.0001; 
**, p=0.79. The number of samples, 24 in each arm. 
Figure 4. Functional analysis of wtN2, nsmN2, delstN2, and rqN2. (A) Flow cytometric 
analysis of CHO(r) clones expressing wtN2, nsmN2, delstN2, and rqN2 at similar expression 
levels. Each clone (cl1 and cl2 represented by green and red lines, respectively) of 
wtN2/CHO(r), nsmN2/CHO(r), delstN2, and rqN2/CHO(r) was analyzed by flow cytometry 
using the anti-human Notch2 antibody MHN2-25 (see Supplemental Fig. 1). Purple curves 
represent isotype control. (B) Western blot analysis of CHO(r) clones expressing wtN2, 
nsmN2, delstN2, and rqN2 using an antibody recognizing the intracellular domain of Notch2. 
Asterisks indicate the transmembrane species of each Notch2 protein. (C) Reporter gene 
transactivation by wtN2, nsmN2, delstN2, and rqN2. Each clone (cl1 and cl2) was cultured in 
a dish coated with human Delta1-Fc (D1-FC) or control immunoglobulin G (IgG). Data are 
means of quadricate experiments. Error bars represent standard deviations. A representative 
experiment from repeated experiments is shown. sRAU, relative arbitrary units standardized 
by β-galctosidase activity. (D) Inhibition of luciferase activity by DAPT, a γ-secretase 
inhibitor. Bulk CHO(r) cells transfected with wtN2 or nsmN2 were stimulated with D1-Fc or 
control IgG with graded concentration of DAPT. 
List of supplementary materials: Supplementary Table1 and Supplementary Figure1 
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Table 1  Characteristics of five patients who had Notch2 mutations  
         
Patient Age/sex CS/IPI* Treatment/Response Survival Others 




W121672 71/M NA†† NA NA - 
L8 66/M  IVA/NA NA  NA  - 
L2 61/F IV/NA CHOP/CR  7 y (alive) BCL2 rearrangement 
W117336 83/F IIIA/LI RT, CHOP*** 0.3 y (d) *** - 
       
*clinical stage/international prognostic index.    
†low intermediate.     
‡THP-adriamycin instead of adriamicin, 4 courses.   
§complete remission uncertain    
||died of advanced lymphoma    
**diabetes mellitus, abdominal aortic aneurysm   
††information not available    
***died of advanced lymphoma after 1st chemotherapy   
 
Table 2 Notch2 mutational status in DLBCL    
       
Sample Disease Nucleic acid change 
Amino acid 
change Copy number 
Immunohistochemistry 
CD10 BCL6 MUM1 
W109539 DLBCL 7454 C/T 2400 Stop  multiple - + + 
W121672 DLBCL 7454 C/T 2400 Stop 3 - + + 
L8 DLBCL 7454 C/T 2400 Stop 2* - + + 
L2 DLBCL 7120 Del A 2288PLKGSTStop  NA - + + 
W117336 DLBCL 7614 G/A 2453 R/Q 2 - + + 
*uniparental disomy for the mutated Notch2 allele is indicated. 




